Cargando…

Intratumoral administration of pro-inflammatory allogeneic dendritic cells improved the anti-tumor response of systemic anti-CTLA-4 treatment via unleashing a T cell-dependent response

Immune checkpoint inhibitors (ICIs) have revolutionized the oncology field. However, a significant number of patients do not respond, at least partly due to the lack of preexisting anti-tumor T-cell immunity. Therefore, it is emergent to add an immune-priming step to improve efficacy. Here, we repor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jin, Chuan, Ali, Arwa, Iskantar, Alexandros, Fotaki, Grammatiki, Wang, Hai, Essand, Magnus, Karlsson-Parra, Alex, Yu, Di
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291714/ https://www.ncbi.nlm.nih.gov/pubmed/35859733 http://dx.doi.org/10.1080/2162402X.2022.2099642

Ejemplares similares

Proinflammatory allogeneic dendritic cells enhance the therapeutic efficacy of systemic anti-4-1BB treatment
por: Ali, Arwa, et al.
Publicado: (2023)

Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models
por: Fotaki, Grammatiki, et al.
Publicado: (2017)

Safe engineering of CAR T cells for adoptive cell therapy of cancer using long‐term episomal gene transfer
por: Jin, Chuan, et al.
Publicado: (2016)

Astrocytes have the capacity to act as antigen-presenting cells in the Parkinson’s disease brain
por: Rostami, Jinar, et al.
Publicado: (2020)

Ilixadencel – an Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration
por: Karlsson-Parra, Alex, et al.
Publicado: (2018)

Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?
por: Tang, Fei, et al.
Publicado: (2018)

Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors
por: Jin, Chuan, et al.
Publicado: (2014)

Phase I trial evaluating safety and efficacy of intratumorally administered inflammatory allogeneic dendritic cells (ilixadencel) in advanced gastrointestinal stromal tumors
por: Fröbom, Robin, et al.
Publicado: (2020)

Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma
por: Laurell, Anna, et al.
Publicado: (2017)

Fascin inhibitor increases intratumoral dendritic cell activation and anti-cancer immunity
por: Wang, Yufeng, et al.
Publicado: (2021)

Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy
por: Georganaki, Maria, et al.
Publicado: (2020)

Induction of systemic and therapeutic antitumor immunity using intratumoral injection of bone-marrow derived dendritic cells genetically modified to express interleukin 12 combined with anti-CTLA-4 antibody
por: Sato-Matsushita, Marimo, et al.
Publicado: (2015)

Pickering emulsions with ethiodized oil and nanoparticles for slow release of intratumoral anti-CTLA4 immune checkpoint antibodies
por: Tselikas, Lambros, et al.
Publicado: (2020)

Preparative immunotherapy with anti-OX40 and anti-CTLA4 improves the response to chemotherapy
por: Friedman, David J, et al.
Publicado: (2014)

Long-term survival in unfavourable-risk mRCC patients after intratumoral administration of a cell-based allogeneic vaccine
por: Karlsson-Parra, Alex, et al.
Publicado: (2015)

Intratumoral heterogeneity impacts the response to anti-neu antibody therapy
por: Song, Hyunkeun, et al.
Publicado: (2014)

Anti-CD40 predominates over anti-CTLA-4 to provide enhanced antitumor response of DC-CIK cells in renal cell carcinoma
por: Zhang, Ying, et al.
Publicado: (2022)

Allogeneic IgG combined with dendritic cell stimuli induces anti-tumor T cell immunity
por: Carmi, Yaron, et al.
Publicado: (2015)

Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers
por: Ock, Chan-Young, et al.
Publicado: (2017)

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
por: Subrahmanyam, Priyanka B., et al.
Publicado: (2018)

Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell–mediated glioma rejection
por: vom Berg, Johannes, et al.
Publicado: (2013)

Revolutionizing anti-tumor therapy: unleashing the potential of B cell-derived exosomes
por: Xiong, Jingwen, et al.
Publicado: (2023)

Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers
por: Shklovskaya, Elena, et al.
Publicado: (2022)

Dendritic cells direct circadian anti-tumour immune responses
por: Wang, Chen, et al.
Publicado: (2022)

CTLA-4 silencing in dendritic cells loaded with colorectal cancer cell lysate improves autologous T cell responses in vitro
por: Ghorbaninezhad, Farid, et al.
Publicado: (2022)

Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response
por: Rupp, Tristan, et al.
Publicado: (2022)

TLR3 Activation of Intratumoral CD103(+) Dendritic Cells Modifies the Tumor Infiltrate Conferring Anti-tumor Immunity
por: Roselli, Emiliano, et al.
Publicado: (2019)

S43. Dendritic cell vaccination combined with CTLA4 blockade
por: Thielemans, K, et al.
Publicado: (2014)

A CTLA-4 blocking strategy based on Nanoboby in dendritic cell-stimulated cytokine-induced killer cells enhances their anti-tumor effects
por: Wang, Wu, et al.
Publicado: (2021)

IFN-I-tolerant oncolytic Semliki Forest virus in combination with anti-PD1 enhances T cell response against mouse glioma
por: Martikainen, Miika, et al.
Publicado: (2021)

CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)
por: Fietz, Simon, et al.
Publicado: (2020)

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
por: Peggs, Karl S., et al.
Publicado: (2009)

Induction of anti-leukemic responses by stimulation of leukemic CD3+ cells with allogeneic stimulator cells
por: Pando, Alejandro, et al.
Publicado: (2018)

IL-10-Engineered Dendritic Cells Modulate Allogeneic CD8(+) T Cell Responses
por: Fortunato, Marta, et al.
Publicado: (2023)

Anti-HIV potency of T-cell responses elicited by dendritic cell therapeutic vaccination
por: Surenaud, Mathieu, et al.
Publicado: (2019)

PB1715: UNLEASHING NATURAL KILLER (NK) CELLS TO PROMOTE ANTI-LEUKEMIC IMMUNITY
por: Tsoukala, Ioanna, et al.
Publicado: (2023)

2081: Phenotypic characterization of the CD4+ T-cell response during anti-CTLA4 therapy with ipilimumab in melanoma patients
por: Sherani, Farha, et al.
Publicado: (2018)

Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells
por: Amaro, Adriana, et al.
Publicado: (2023)

Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment
por: Demaria, Sandra, et al.
Publicado: (2013)

IL36 Cooperates With Anti-CTLA-4 mAbs to Facilitate Antitumor Immune Responses
por: Qu, Qiuxia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ptapvlku8tf1jpeglkrdu3vkb9